Relmada appoints Johns Hopkins professor to clinical advisory board

CORAL GABLES, Fla. - Relmada Therapeutics, Inc. (NASDAQ:RLMD), a $69 million market cap biotech company currently rated ’FAIR’ by InvestingPro’s Financial Health scoring system, announced Tuesday the appointment of Dr. Max Kates to its Clinical Advisory Board to support development of NDV-01, a treatment for non-muscle invasive bladder cancer (NMIBC).

Dr. Kates, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, will provide expertise for the company’s planned Phase 3 program for NDV-01, expected to begin in the first half of 2026. The company’s stock has shown remarkable momentum, with a 700% price return over the past six months, reflecting investor optimism around its development programs.

"Max’s experience chairing the landmark Phase 3 BRIDGE trial and leading several other practice-changing studies gives him a unique clinical perspective that will be invaluable," said Dr. Raj Pruthi, Chief Medical Officer-Urology at Relmada.

NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel designed to enable bladder retention and gradual drug release over 10 days. The treatment can be administered in-office in less than 10 minutes without anesthesia or specialized equipment, according to the company.

Dr. Kates currently serves as chair of the Phase 3 EA8212 BRIDGE Trial comparing Gemcitabine/Docetaxel to BCG in non-muscle invasive bladder cancer. He is also the R. Christian B. Evensen Professor of Urology and Director of the Division of Urologic Oncology at Johns Hopkins Hospital.

NMIBC represents 75-80% of all bladder cancer cases with over 744,000 prevalent cases in the U.S. The condition is associated with high recurrence rates of 50-80% over five years.

Initial safety and efficacy data for NDV-01 was presented at the American Urologic Association in April 2025 and updated in August, according to the company’s press release statement. While the company maintains a strong liquidity position with a current ratio of 4.11 and more cash than debt on its balance sheet, InvestingPro analysis reveals additional insights about Relmada’s financial health and market position. Discover comprehensive analysis and 8 more exclusive ProTips by accessing the detailed Pro Research Report, part of the in-depth coverage available for over 1,400 US stocks.

In other recent news, Relmada Therapeutics reported its second-quarter 2025 earnings, revealing a narrower-than-expected loss. The company achieved an earnings per share of -$0.30, surpassing analysts’ predictions of -$0.40. This result marks a 25% positive surprise, indicating improved financial management. Additionally, Relmada Therapeutics highlighted progress in its clinical pipeline, including a 91% complete response rate for its NDV-01 treatment for non-muscle invasive bladder cancer in Phase 2 trials. The drug is set to enter a Phase 3 registrational trial in the first half of 2026. Furthermore, Raj S. Pruthi, MD, the Chief Medical Officer-Urology, purchased 55,000 shares of the company’s stock in open market transactions, as reported in a recent SEC filing. These recent developments provide a glimpse into the company’s strategic and financial directions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.